Cytopharma

Cytopharma is the first pharmaceutical company in Africa & Middle East region that is fully dedicated to the manufacturing and marketing of generic cytotoxic drugs. We care about your patients Established in Tunisia since 2011, Cytopharma's purpose is to provide high quality and affordable oncology medicine for cancer patients all over the world, helping them successfully fighting the disease. Cytopharma has a production line of injectable oncology products in both liquid and lyophilized forms. Our steadily growing product portfolio is currently counting five molecules : Fluorouracil (5-FU) - 250, 500 and 1000 mg Oxaliplatin - 50 and 100 mg Epirubicin - 10 and 50 mg Paclitaxel - 30, 100 and 150 mg Docetaxel - 20 and 80 mg As we are expanding our business towards Africa, Middle East and Europe, we are open to any kind of partnership : distribution, contract manufacturing, co-promotion, co-marketing ...

Symbio Proinnovera

The newly announced merger of NY-headquartered Symbio LLC and CA-headquartered Dow Development Laboratories LLC with Munster (Germany)-based Proinnovera will form Symbio Proinnovera, creating one of the world’s largest specialized dermatology-focused clinical research organizations. Founded over 20 years ago, the Symbio & Dow Group has a full-service clinical trial CRO offering for dermatology, complemented by a business active in the pre-clinical formulation of topicals, providing its client's dermatology and aesthetics services - from pre-clinical formulation work to subsequent clinical trial execution. Proinnovera was founded 25 years ago and is a leading European CRO in the dermatology clinical trial space. It is a full-service CRO conducting clinical studies from Phase I to IV, as well as non-interventional and medical device studies. Proinnovera turns study data into oversight for clients to accelerate decision-making, increasing transparency and efficiency in the conduct of clinical trials. Both companies are proven market leaders among specialty dermatology CROs with exceptional geographical coverage. Their combined strength will enable them to excel at addressing customers’ needs and expectations in all areas of research. The newly formed organization will leverage the combined power of two highly experienced teams with deep expertise in the dermatology space to generate efficiencies and accelerate clinical research. Symbio Proinnovera will be supported in its growth by ARCHIMED, a leading investment firm focused exclusively on healthcare industries.

4C Pharma Solutions

A comprehensive global healthcare solutions company specializing in end to end of Pharmacovigilance, Materiovigilance, Medical Information Call Center, Hosting, Regulatory Affairs, Medical Affairs, CDM & Staff Augmentation.

Olympia Pharmaceuticals

Start Feeling the Olympia Difference: Olympia Pharmaceuticals serves patients nationwide to help improve their health through a variety of wellness products. Olympia specializes in IV nutrition, sexual health, weight management, vein care, hormone replacement therapy, and more. With two state of the art facilities, Olympia is a single source pharmacy for patients and physicians across the country. As an FDA registered outsourcing facility, Olympia can provide prescription medications for office use.

lexicon pharmaceuticals, inc.

Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.